156 - Big Beasts of Clinical Mycology

Tuesday, October 21, 2025

1:45 PM - 3:00 PM US ET

Location: Ballroom (Hall B1)

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

GT

George Thompson, III, MD

Professor
Internal Medicine, Division of Infectious Diseases
University of California Davis Medical Center
Sacramento, CA, United States
Adriana Rauseo, MD

Assistant Professor, Division of Infectious Diseases
Washington University in St. Louis
Saint Louis, MO, United States

Faculty(s)

LO

Luis Ostrosky-Zeichner, MD (he/him/his)

Professor of Medicine
Division of Infectious Diseases
University of Texas Health Science Center
Houston, Texas, United States
MS

Monica Slavin, MBBS,MD

Professor
National Centre for Infections in Cancer, Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Dimitrios P. Kontoyiannis, MD, MS, ScD, PhD (he/him/his)

Professor • Infectious Diseases
The University of Texas MD Anderson Cancer Center
Houston, TX, United States

Disclosure(s):

George R. Thompson, MD, III: Astellas Pharma Inc.: Advisor/Consultant, Grant/Research Support; Basilea Pharmaceutica: Advisor/Consultant, Grant/Research Support; Elion Therapeutics: Advisor/Consultant; F2G Limited: Advisor/Consultant, Grant/Research Support; GSK/ViiV Healthcare: Advisor/Consultant, Grant/Research Support; Pfizer, Inc.: Advisor/Consultant; Scynexis Inc.: Advisor/Consultant, Grant/Research Support

Adriana Rauseo, MD: No financial relationships to disclose.

Luis Ostrosky-Zeichner, MD: Basilea: Advisor/Consultant, Grant/Research Support, Honoraria; Eurofins Viracor: Advisor/Consultant, Grant/Research Support, Honoraria; F2G: Advisor/Consultant, Grant/Research Support, Honoraria; Gilead: Advisor/Consultant, Grant/Research Support, Honoraria; GSK: Advisor/Consultant, Grant/Research Support, Honoraria; Melinta: Advisor/Consultant, Grant/Research Support, Honoraria; Pfizer: Advisor/Consultant, Grant/Research Support, Honoraria; Pulmocide: Advisor/Consultant, Grant/Research Support, Honoraria; Scynexis: Advisor/Consultant, Grant/Research Support, Honoraria; T2 Biosystems: Advisor/Consultant, Grant/Research Support, Honoraria

Monica Slavin, MBBS,MD: Basilea: Advisor/Consultant; Cidara Therapeutics: Advisor/Consultant; Elion: Advisor/Consultant; F2G Limited: Grant/Research Support; Gilead Biosciences: Advisor/Consultant, Grant/Research Support; Merck and Co: Grant/Research Support; Pfizer, Inc.: Advisor/Consultant, Grant/Research Support; Roche Inc: Advisor/Consultant

Dimitrios P. Kontoyiannis, MD, MS, ScD, PhD: No financial relationships to disclose.

Learning Objectives:

At the conclusion of this session, participants will be able to:

explain the emergence and treatment approach to rare mould infections;
describe the treatment approach to resistant and/or refractory candidiasis;
evaluate and treat patients with fusariosis.

Presentations:

1:45 PM - 2:10 PM US ET

Rare Molds (Scedosporium, Lomentospora, Scopulariopsis)
Speaker: Monica Slavin, MBBS,MD – National Centre for Infections in Cancer, Peter MacCallum Cancer Centre
2:10 PM - 2:35 PM US ET

Drug-Resistant and Refractory Candida Infections
Speaker: Luis Ostrosky-Zeichner, MD (he/him/his) – University of Texas Health Science Center
2:35 PM - 3:00 PM US ET

Fusariosis and Other Rare Molds
Speaker: Dimitrios P. Kontoyiannis, MD, MS, ScD, PhD (he/him/his) – The University of Texas MD Anderson Cancer Center